GlobeNewswire Inc.··Not SpecifiedNuvectis Pharma to Showcase NXP900 Cancer Drug Data at 2026 AACR Meeting
Nuvectis Pharma will present three posters on NXP900, a first-in-class cancer inhibitor, at April's AACR Meeting in San Diego, highlighting combination and immunotherapy potential.
NVCTprecision medicineoncology